down arrow

Bausch Health Cos., Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA0717341071
CAD
10.32
0.47 (4.77%)

Dec 04

TSE

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

9.8610.52

52 Week

5.9112.07
Valuation
Technical
Day's Volume

CASH

569.84 k

Shareholding (Mar 2025)

FII

56.93%

Held by 436 FIIs

DII

31.0%

Held by 32 DIIs

Promoter

9.44%

What does Bausch Health Cos., Inc. do?

22-Jun-2025

Bausch Health Companies Inc. is a Canadian firm that develops, manufactures, and markets branded and generic pharmaceuticals, medical devices, and over-the-counter products, with a market cap of CAD 3,900.28 million. Key financial metrics include a P/E ratio of 13.00 and a return on equity of 1.10%.

Overview:<BR>Bausch Health Companies Inc. is a Canada-based company that develops, manufactures, and markets a range of branded and generic pharmaceuticals, medical devices, and over-the-counter products in the Pharmaceuticals & Biotechnology industry, with a market cap of CAD 3,900.28 Million.<BR><BR>Financial Snapshot:<BR>Market cap: CAD 3,900.28 Million (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: 13.00<BR>Dividend Yield: 0.00%<BR>Debt Equity: -18.35<BR>Return on Equity: 1.10%<BR>Price to Book: -3.31<BR><BR>Contact Details:<BR>Address: 2150 Saint-Elzear Blvd W, LAVAL QC: H7L 4A8<BR>Tel: ['1 514 7446792', '1 949 4616002']<BR>Fax: 1 514 7446272<BR>Website: https://www.bauschhealth.com/

Read More

Who are in the management team of Bausch Health Cos., Inc.?

22-Jun-2025

As of March 2022, the management team of Bausch Health Cos., Inc. includes Mr. Joseph Papa as Chairman and CEO, and Mr. Thomas Ross as Lead Independent Director, along with independent directors Mr. Richard De Schutter, Mr. D. Robert Hale, Dr. Argeris Karabelas, and Ms. Sarah Kavanagh.

As of March 2022, the management team of Bausch Health Cos., Inc. includes Mr. Joseph Papa, who serves as the Chairman of the Board and Chief Executive Officer. Additionally, the board features Mr. Thomas Ross as the Lead Independent Director, along with independent directors Mr. Richard De Schutter, Mr. D. Robert Hale, Dr. Argeris Karabelas, and Ms. Sarah Kavanagh. <BR><BR>In summary, as of March 2022, the key members of the management team at Bausch Health Cos., Inc. are Mr. Joseph Papa, Mr. Thomas Ross, and several independent directors including Mr. Richard De Schutter, Mr. D. Robert Hale, Dr. Argeris Karabelas, and Ms. Sarah Kavanagh.

Read More

Is Bausch Health Cos., Inc. technically bullish or bearish?

25-Jun-2025

As of October 1, 2023, Bausch Health Cos., Inc. shows a neutral technical stance with mixed signals, indicating mildly bearish strength on daily and monthly charts, while weekly indicators suggest a mildly bullish trend.

As of 1 October 2023, the technical stance for Bausch Health Cos., Inc. is currently neutral with a mildly bearish strength. The weekly MACD indicates a mildly bullish sentiment, while the monthly MACD is bearish. The Bollinger Bands show a mildly bullish trend on the weekly chart but a mildly bearish trend on the monthly chart. Daily moving averages are mildly bearish, and the KST is mildly bullish weekly but bearish monthly. Dow Theory reflects a no trend on the weekly chart and mildly bullish on the monthly chart. Overall, the mixed signals across different time frames suggest a lack of clear direction.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CAD 3,900 Million ()

stock-summary
P/E

16.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-18.35

stock-summary
Return on Equity

1.10%

stock-summary
Price to Book

-3.31

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
3.41%
0%
3.41%
6 Months
62.26%
0%
62.26%
1 Year
-9.79%
0%
-9.79%
2 Years
1.88%
0%
1.88%
3 Years
-3.37%
0%
-3.37%
4 Years
-66.11%
0%
-66.11%
5 Years
-59.53%
0%
-59.53%

Bausch Health Cos., Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
0
EBIT to Interest (avg)
0.95
Debt to EBITDA (avg)
7.08
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.39
Tax Ratio
31.62%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
75.63%
ROCE (avg)
6.50%
ROE (avg)
20.29%
Valuation key factors
Factor
Value
P/E Ratio
16
Industry P/E
Price to Book Value
NA
EV to EBIT
NA
EV to EBITDA
EV to Capital Employed
NA
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
ROE (Latest)
NA
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 16 Schemes (2.63%)

Foreign Institutions

Held by 436 Foreign Institutions (56.93%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
0.00
0.00
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
0.00
0.00
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
0.00
0.00
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
0.00
0.00
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Bausch Health Cos., Inc. stock-summary
stock-summary
Bausch Health Cos., Inc.
Pharmaceuticals & Biotechnology
Bausch Health Companies Inc, formerly Valeant Pharmaceuticals International Inc, is a Canada-based company that develops, manufactures and markets a range of branded and generic pharmaceuticals, medical devices and over-the-counter products. It primarily develops products in the therapeutic areas of eye health, gastroenterology and dermatology. Its dermatology products treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis and other dermatoses. It also offers a selection of aesthetic medical devices that address a variety of conditions, including facial wrinkles, acne, pigmentation conditions and laser hair removal, among others. The gastrointestinal (GI) segment offers products that treat GI and hepatologic conditions, including hepatic encephalopathy, irritable bowel syndrome with diarrhea and ulcerative colitis, among others. Its eye health products are marketed in the following categories: Contact Lens, Pharmaceutical Products and Surgical.
Company Coordinates stock-summary
Company Details
2150 Saint-Elzear Blvd W , LAVAL QC : H7L 4A8
stock-summary
Tel: 1 514 74467921 949 4616002
stock-summary
https://www.bauschhealth.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."